trial summary · NCT07153055
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Trial record from the TrialBase DB dataset, status RECRUITING, condition Small Cell Lung Cancer ( SCLC ), sponsored by Misty Shields. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
Source record: https://clinicaltrials.gov/study/NCT07153055
Facts
| registry id | NCT07153055 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Small Cell Lung Cancer ( SCLC ) |
| sponsor | Misty Shields |
| sponsor class | OTHER |
| enrollment | 16 |
| start date | 2027-01 |
| primary completion | 2029-04 |
| completion | 2029-10 |
| results posted | not reported |
Conditions
- Small Cell Lung Cancer ( SCLC )
- Transformed Small Cell Lung Cancer
Interventions
- Lurbinectedin
- Osimertinib
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.